The current financial score of Bio Rad Laboratories Inc is 8.02. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 656.40M, representing a year-over-year increase of 0.52%, while its net profit experienced a year-over-year increase of 234.13%.
The current valuation score of Bio Rad Laboratories Inc is 8.58. Its current P/E ratio is 63.28, which is 2.30% below the recent high of 64.74 and 210.37% above the recent low of -69.84.
The current earnings forecast score of Bio Rad Laboratories Inc is 6.00. The average price target is 395.00, with a high of 440.00 and a low of 350.00.
The current price momentum score of Bio Rad Laboratories Inc is 3.34. Currently, the stock price is trading between the resistance level at 398.72 and the support level at 355.86, making it suitable for range-bound swing trading.
The current institutional shareholding score of Bio Rad Laboratories Inc is 7.00. The latest institutional shareholding proportion is 84.86%, representing a quarter-over-quarter decrease of 16.47%.
The current risk assessment score of Bio Rad Laboratories Inc is 7.71. The company's beta value is 1.09. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.